Rejection episodes did not correlate with increasing EBV-specific immunity. All patients had stable or decreasing EBV immune response, as evaluated by ELISpot assay (and reported in IFN-γ spot forming cells (SFC) per100 000 cells). Mononuclear cells isolated from peripheral blood samples were cocultured with LCLs; after 10 days, cells were evaluated by ELISpot to assess IFN-γ release when plated with LCLs. Patient A1 had no evidence of EBV-specific immune response at time of rejection (A). EBV-specific immune response were decreasing at time of rejection in patients C3 and A12 (B-C). ∗ indicates that data were not available at these time points. IFN-γ, interferon gamma; SFC, spot forming cells.